Zentalis appoints Jan Skvarka as Class III director, cures Nasdaq listing compliance

Zentalis Pharmaceuticals, Inc.

Jan Skvarka, Ph.D., M.B.A., appointed as Class III director effective September 9, 2022.
Appointment to Audit and Nominating Committees cures Nasdaq Listing Rule 5605(c)(2) non-compliance.
Initial term expires at 2023 annual meeting; receives standard director compensation.
Granted RSUs covering 36,606 shares (value ~$1M) vesting over three years.
Also eligible for annual RSU grant (~$500k) and committee retainers ($10k audit, $5k nominating).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jan Skvarka

Class III director

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2022-09-09
Filed: September 12, 2022, 7:59 PM ET

On and effective September 9, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Jan Skvarka, Ph.D., M.B.A., as a Class III director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jan Skvarka was appointed as Class III director at Zentalis Pharmaceuticals, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On and effective September 9, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Jan Skvarka, Ph.D., M.B.A., as a Class III director.

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-22-000163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.